Status: Ongoing
First registered on:
04/02/2020
Last updated on:
29/07/2020
1. Study identification
EU PAS Register NumberEUPAS33448
Official titlePRECISE/Rates of bone fractures and survival in metastatic castration-resistant PRostate cancer (mCRPC) PatiEnts treated with Radium-223 in routine Clinical practIce in SwedEn
Study title acronymPRECISE
Study typeObservational study
Brief description of the study
Was this study requested by a regulator?Yes: EMA
Is the study required by a Risk Management Plan (RMP)?
EU RMP category 1 (imposed as condition of marketing authorisation)
Regulatory procedure number (RMP Category 1 and 2 studies only)EMEA/H/C/PSP/S/0076
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsRTI-HS
Department/Research group
Organisation/affiliation
Details of (Primary) lead investigator
Title Professor
Last name Stattin
First name Pär
Is this study being carried out with the collaboration of a research network?
Yes
The Prostate Cancer data Base Sweden (PCBaSe)
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
Sweden
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed05/12/201805/12/2018
Start date of data collection15/02/202015/02/2020
Start date of data analysis
Date of interim report, if expected
Date of final study report30/06/2021
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesBayer AG100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name BAYER AG
First name Bayer Clinical Trials
Address line 1Muellerstrasse 178
Address line 2
Address line 3
CityBerlin
Postcode13342
CountryGermany
Phone number (incl. country code)49-30300139005
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Dr
Last name BAYER AG
First name Bayer Clinical Trials
Address line 1Muellerstrasse 178
Address line 2
Address line 3
CityBerlin
Postcode13342
CountryGermany
Phone number (incl. country code)49-30300139005
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Product NameXofigo
CountrySweden
Substance INN(s)RADIUM RA 223 DICHLORIDE
7. Medical conditions to be studied
Medical condition(s)Yes
Prostate cancer metastatic
8. Population under study
Age
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
9. Number of subjects
Estimated total number of subjects3800
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources not registered with ENCePP
PCBaSE, Sweden
Sources of data
Disease/case registry
11. Scope of the study
What is the scope of the study?
Risk assessment
Primary scope : Risk assessment
12. Main objective(s)
What is the main objective of the study?
The primary objective in this study is to estimate the effect of Ra-223 on the incidence of bone fractures compared with other standard treatments for mCRPC.
Are there primary outcomes?Yes
1. Bone fractures requiring admission to a hospital or treated in an outpatient setting, as recorded or captured in the PCBaSe。
Are there secondary outcomes?Yes
1. Death due to all causes
2. Death due to prostate cancer
13. Study design
What is the design of the study?
Cohort study
14. Follow-up of patients
Will patients be followed up?Yes
Please describe duration of follow up
The follow-up is 1 year.
15. Data analysis plan
Please provide a brief summary of the analysis method
The primary outcome will be the incidence of bone fractures. The numerator will be the number of symptomatic bone fractures identified during Ra-223 use, and the denominator will be the sum of all person-years of follow-up for symptomatic bone fractures. The secondary outcomes are death due to all causes and death due to prostate cancer.
The cumulative incidence of bone fractures, all-cause mortality, and prostate cancer–specific mortality will be estimated using the Kaplan-Meier estimator, and 95% confidence intervals will be computed using Greenwood’s formula.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
